An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer.

Bibliographic Details
Title:	An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer.
Authors:	Cavalieri, Stefano^1,2 (AUTHOR) stefano.cavalieri@istitutotumori.mi.it, Serafini, Mara Serena³ (AUTHOR), Carenzo, Andrea³ (AUTHOR), Canevari, Silvana⁴ (AUTHOR), Lenoci, Deborah³ (AUTHOR), Pistore, Federico¹ (AUTHOR), Miceli, Rosalba⁵ (AUTHOR), Vecchio, Stefania⁶ (AUTHOR), Ferrari, Daris⁷ (AUTHOR), Moro, Cecilia⁸ (AUTHOR), Sponghini, Andrea⁹ (AUTHOR), Caldara, Alessia¹⁰ (AUTHOR), Rocca, Maria Cossu¹¹ (AUTHOR), Secondino, Simona¹² (AUTHOR), Moretti, Gabriella¹³ (AUTHOR), Denaro, Nerina¹⁴ (AUTHOR), Caponigro, Francesco¹⁵ (AUTHOR), Vaccher, Emanuela¹⁶ (AUTHOR), Rinaldi, Gaetana¹⁷ (AUTHOR), Ferraù, Francesco¹⁸ (AUTHOR)
Source:	Cells (2073-4409). Oct2022, Vol. 11 Issue 19, p3176. 11p.
Subject Terms:	CETUXIMAB, HEAD & neck cancer, EPIDERMAL growth factor receptors, PROGRESSION-free survival, CANCER chemotherapy, PROGNOSIS
Abstract:	Epidermal growth factor receptor (EGFR) pathway has been shown to play a crucial role in several inflammatory conditions and host immune-inflammation status is related to tumor prognosis. This study aims to evaluate the prognostic significance of a four-gene inflammatory signature in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients treated with the EGFR inhibitor cetuximab plus chemotherapy. The inflammatory signature was assessed on 123 R/M HNSCC patients, enrolled in the multicenter trial B490 receiving first-line cetuximab plus platinum-based chemotherapy. The primary endpoint of the study was progression free survival (PFS), while secondary endpoints were overall survival (OS) and objective response rate (ORR). The patient population was subdivided into 3 groups according to the signature score groups. The four-genes-signature proved a significant prognostic value, resulting in a median PFS of 9.2 months in patients with high vs. 6.2 months for intermediate vs. 3.9 months for low values (p = 0.0016). The same findings were confirmed for OS, with median time of 18.4, 13.4, and 7.5 months for high, intermediate, and low values of the score, respectively (p = 0.0001). When ORR was considered, the signature was significantly higher in responders than in non-responders (p = 0.0092), reaching an area under the curve (AUC) of 0.65 (95% CI: 0.55–0.75). Our findings highlight the role of inflammation in the response to cetuximab and chemotherapy in R/M-HNSCC and may have translational implications for improving treatment selection. [ABSTRACT FROM AUTHOR]
	Copyright of Cells (2073-4409) is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database:	Academic Search Complete
Full text is not displayed to guests.	Login for full access.

More Details
ISSN:	20734409
DOI:	10.3390/cells11193176
Published in:	Cells (2073-4409)
Language:	English